Andrew Lane
Hematology & Oncology · Boston, MANPI 1144372111
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $125,782 of the $135,350 with a category attached, or 92.9%. Qiagen, LLC accounts for 82.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $28,380, more than ten times the $92 reported in 2019. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $1573.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Qiagen, LLC$112K
- Stemline Therapeutics Inc.$19K
- Merck$2K
- Sanofi$2K
Across 174 payments — averaging $12,081 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stemline Therapeutics Inc.$1.9M
- AbbVie$148K
- Adaptimmune LLC$9K
What the payments were for
- Consulting fees$125,78293%
- Speaking & faculty fees$8,7006%
- Food & beverage$8681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Qiagen, LLC | 70 | $111,750 |
| Stemline Therapeutics Inc. | 12 | $18,876 |
| Merck | 3 | $2,492 |
| Sanofi | 1 | $2,232 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,350 in reported general payments places this provider in the 90th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.